Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea
- PMID: 26045597
- PMCID: PMC4458806
- DOI: 10.1182/blood-2015-03-635391
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea
References
-
- Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77–78. - PubMed
-
- Charache S, Terrin ML, Moore RD, et al. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical